MedTrace Logo

Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women

NCT00682721 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-03-02

No results posted yet for this study

Summary

We will be examining the effects of suppressive valacyclovir therapy on the stability of vaginal flora in women who are seropositive for HSV-2. We have preliminary data that suggests the presence of HSV-2 increases the risk for Group B Streptococcus colonization as well as many other deleterious organisms (e.g. Streptococcus pseudoporcinus), in addition to increasing the risk for acquisition of BV-associated vaginal flora. We will be examining the effects of suppressive therapy on the vaginal flora of any HSV-2 seropositive woman.

Conditions

  • Bacterial Vaginosis
  • Herpes Simplex Virus Type II

Interventions

DRUG

Placebo

Matching placebo two pills once daily

DRUG

Valacyclovir

1 gram daily x number of days active in the study

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Thomas L Cherpes, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00682721 on ClinicalTrials.gov